sermorelin
Sign in to saveSermorelin acetate (; brand names Geref, Gerel), also known as GHRH (1-29), is a peptide analogue of growth hormone-releasing hormone (GHRH) which is used as a diagnostic agent to assess growth hormone (GH) secretion for the purpose of diagnosing growth hormone deficiency. It is a 29-amino acid polypeptide representing the 1–29 fragment from endogenous human GHRH, thought to be the shortest fully functional fragment of GHRH.
Research
330 papers- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2026
- Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?Clinical interventions in aging · 2006
- Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021
- A potentially effective drug for patients with recurrent glioma: sermorelin.Annals of translational medicine · 2021
- Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 1999
via PubMed
Wikidata facts
- Mass
- 3356.822054
Show 2 more facts
- chemical formula
- C₁₄₉H₂₄₆N₄₄O₄₂S
- NCI Thesaurus ID
- C62088
Sources (1)
via Wikidata · CC0
~3 min read
Article
5 sectionsContents
- Medical usage
- Mechanism of action
- Research potential
- See also
- References
Sermorelin acetate (; brand names Geref, Gerel), also known as GHRH (1-29), is a peptide analogue of growth hormone-releasing hormone (GHRH) which is used as a diagnostic agent to assess growth hormone (GH) secretion for the purpose of diagnosing growth hormone deficiency. It is a 29-amino acid polypeptide representing the 1–29 fragment from endogenous human GHRH, thought to be the shortest fully functional fragment of GHRH.
Sermorelin was approved by the US Food and Drug Administration (FDA) in 1997 for use as a treatment for children with growth hormone deficiency or growth failure. However, as of 2008, the manufacturer discontinued the production of Sermorelin for commercial reasons, and it is no longer available as an FDA-approved drug. Despite this, it may still be used in some off-label contexts or obtained through compounding pharmacies.
Available in 7 languages
via Wikidata sitelinks · CC0